הודעות, עדכונים וחדשות
Adding Radium-223 to Abiraterone Shows No Survival Advantage in mCRPC
Adding radium-223 dichloride (Xofigo) to abiraterone acetate (Zytiga) and prednisone did not improve survival in patients with metastatic castration-resistant prostate cancer (mCRPC), according to findings presented at the 2018 ESMO Congress
Avelumab/Axitinib Nearly Doubles PFS, ORR in Frontline RCC
The combination of avelumab (Bavencio) and axitinib (Inlyta) doubled objective response rates (ORRs) and significantly improved progression-free survival (PFS) compared with sunitinib (Sutent) in patients with treatment-naïve advanced renal cell carcinoma
המייל האדום של מדנט
פספסנו ידיעה חשובה? דווחו אתם לנו - חדשות, מחקרים, סקירות וידיעות מעניינות. עזרו לנו לספק את מירב התוכן האיכותי עבורכם
לחצו עכשיו לשליחת ידיעה
Tumor Mutation Burden as a Biomarker in Resected Non–Small-Cell Lung Cancer
A report on findings from the Lung Adjuvant Cisplatin Evaluation (LACE)-Bio-II study, in which researchers analyzed next-generation sequencing and long-term outcomes data from > 900 patients with early-stage NSCLC treated prospectively in adjuvant landmark clinical trials
עדכונים בסוכרת סוג 1
30.04.2018
